https://www.selleckchem.com/pr....oducts/ro-31-8220-me
erformance on multiple outcomes and has more evidence available. New molecules Eculizumab, Tocilizumab, Satralizumab are good options for treatment. Drugs like Azathioprine and Mycophenolate are effective, but with a worse risk-benefit ratio, therefore, they are useful alternatives in places that do not have access to monoclonal antibodies. Our results suggest that monoclonal antibodies are highly effective and safe for the treatment of NMOSD; Rituximab showed better performance on multiple outcomes and has more evidence ava
Like
Comment
Share
